Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Background In the international, phase III, randomized, double-blind CORRECT trial, regorafenib significantly prolonged overall survival (OS) versus placebo in patients with metastatic colorectal cancer (mCRC) that had progressed on all standard therapies. This post hoc analysis evaluated the effica...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Invest New Drugs
Autori principali: Yoshino, Takayuki, Komatsu, Yoshito, Yamada, Yasuhide, Yamazaki, Kentaro, Tsuji, Akihito, Ura, Takashi, Grothey, Axel, Van Cutsem, Eric, Wagner, Andrea, Cihon, Frank, Hamada, Yoko, Ohtsu, Atsushi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2014
Soggetti:
Phase III Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434855/
https://ncbi.nlm.nih.gov/pubmed/25213161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0154-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi